ARTH Arch Therapeutics Inc.

Arch Therapeutics, Inc. is a development stage biotechnology company, which engages in the development and provision of hemostasis and sealant technology platform. Its product candidates include AC5 Devices, which designed to achieve hemostasis during surgical, wound, and interventional care. The company was founded by Rutledge Ellis-Behnke and Terrence W. Norchi on September 16, 2009 and is headquartered in Framingham, MA.

This security is traded over-the-counter, or OTC. We don't always have accurate pricing data on OTC stocks.

$0.13    OTCQB
As of 05/07/2021     OTCMarkets


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  
IPO date:  05/20/2013
Outstanding shares:  193,594,766
Average volume:  228,057
Market cap:   $24,683,333
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    
ISIN:        
Sedol:      
Valuation   (See tab for details)
PE ratio:   -16.20
PB ratio:   -149.90
PS ratio:   0.00
Return on equity:   -255.65%
Net income %:   -52,451.39%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy